Table 4.
Outcomes.
| Author,Year | Study Group | Pain Score at rest 24 h (Mean[SD]) | Pain Score at rest 24 h (Median [Range]) | Pain Score with ambulation 24 h (Mean[SD]) | Pain Score with ambulation 24 h (Median[Range]) | Pain Score at rest 4 h (Mean[SD]) | Pain Score at rest 4 h (Median[Range]) | Pain Score with ambulation 4 h (Mean[SD]) | Pain Score with ambulation 4 h (Median[Range]) |
|---|---|---|---|---|---|---|---|---|---|
| Backes JR et al. [9] | Group 1 (control) |
*39.6 (−) | – | – | – | – | – | – | – |
| Group 2 (dex + zofran) | 19.6 (−) | – | – | – | – | – | – | – | |
| Group 3 (dex + zofran + dex) | |||||||||
| Lunn TH et al. [10] | Group 1 (control) | – | 46.45 (10–76.1) | – | 69.5 (32–88.5) | – | 26.25 (10.5–68) | – | 44.8 (14–74) |
| Group 2 (methylpred) | – | *19.15 (1.5–36) | – | *26.8 (10.5–62) | – | *15.6 (0−51) | – | *19.05 (1–58.5) | |
| Lunn TH et al. [11] | Group 1 (control) | – | 10.15 (0–44.8) | 38.15 (11.6–75) | – | 6.05 (0−51.9) | – | 29.65 (1.7–64.4) | |
| Group 2 (methylpred) | – | 5.35 (0–39.4) | 22.65 (0–48) | – | 19.15 (0−47.4) | – | 26 (0–51.9) | ||
| Koh IJ et al. [12] | Group 1 (Ra) | 40 (20) | – | – | – | – | – | – | – |
| Group 2 (dex + Ra) | *24 (10) | – | – | – | – | – | – | – | |
| Mathiesen O et al. [13] | Group 1 (control) | 12.9 (12.9) | – | 31.7 (19.6) | – | 18.5 (18.2) | – | 22.4 (18.8) | – |
| Group 2 (pregabalin) | 12.8 (11.2) | – | 30.1 (21.3) | – | 16.1 (16.2) | – | 19.1 (20.7) | – | |
| Group 3 (pregabalin + dex) | 12.9 (15.8) | – | 27.6 (19.7) | – | 11.6 (18.8) | – | 14.4 (22.2) | – | |
| Kardash KJ et al. [14] | Group 1 (control) | 19 (18) | – | *69 (−) | – | 25 (20) | – | – | – |
| Group 2 (dex) | 15 (11) | – | 26 (−) | – | 21 (21) | – | – | – | |
Note: *indicates statistically significant difference between experimental groups; pain scores converted to 0–100 scale